Methods of diagnosing pre-eclampsia or eclampsia

Details Methods of diagnosing pre-eclampsia or eclampsia Methods of diagnosing pre-eclampsia or eclampsia

2003-07-21

2008-08-05

Landsman, Robert (Department: 1647)

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

Hormone or other secreted growth regulatory factor,...

C435S007100, C435S007200, C514S002600, C514S012200, C530S350000

Reexamination Certificate

active

07407659

ABSTRACT:
Disclosed herein are methods for diagnosing pre-eclampsia and eclampsia. Also disclosed herein are methods for treating pre-eclampsia and eclampsia using compounds that increase VEGF or PlGF levels or compounds that decrease sFlt-1 levels. Compounds that inhibit the binding of VEGF or PlGF to sFlt1—are also disclosed herein for the treatment of pre-eclampsia or eclampsia.

REFERENCES:
patent: 5194596 (1993-03-01), Tischer et al.
patent: 5219739 (1993-06-01), Tischer et al.
patent: 5238819 (1993-08-01), Roberts et al.
patent: 5240848 (1993-08-01), Keck et al.
patent: 5332671 (1994-07-01), Ferrara et al.
patent: 5543138 (1996-08-01), Keith
patent: 5712395 (1998-01-01), App et al.
patent: 5763441 (1998-06-01), App et al.
patent: 5830879 (1998-11-01), Isner
patent: 6100071 (2000-08-01), Davis-Smyth et al.
patent: 6258787 (2001-07-01), Isner
patent: 6365157 (2002-04-01), Rockwell et al.
patent: 6399585 (2002-06-01), Larson et al.
patent: 6410322 (2002-06-01), Robinson
patent: 6447768 (2002-09-01), van Zonneveld et al.
patent: 6677300 (2004-01-01), Schreiner et al.
patent: 2003/0114412 (2003-06-01), Ward et al.
patent: 2003/0144298 (2003-07-01), Curwen et al.
patent: 2003/0220262 (2003-11-01), Schreiner et al.
patent: 2004/0038305 (2004-02-01), Poston et al.
patent: 2005/0025762 (2005-02-01), Karumanchi et al.
patent: 2005/0148023 (2005-07-01), Thadhani et al.
patent: 2005/0148040 (2005-07-01), Thadhani et al.
patent: 2005/0170444 (2005-08-01), Karumanchi et al.
patent: 2006/0183175 (2006-08-01), Buhimschi et al.
patent: 1417971 (2004-05-01), None
patent: WO 98/28006 (1998-07-01), None
patent: WO 02/37120 (2002-05-01), None
patent: WO 2006/069373 (2006-06-01), None
Maynard et al., Soluble Fms-like tyrosine kinase 1 and endothelial dysfunction in the pathogenesis of preeclampsia, 2005, Pediatric Research, vol. 57, No. 5, Part 2, pp. 1R-7R.
Ferrara, N. Role of vascular endothelial growth factor in the regulation of angiogenesis, 1999, Kidney International, vol. 56, pp. 794-814.
Torry et al., Expression and function of placental growth factor: implications for abnormal placentation, 2003, Journal Society of Gynecology Investigation, vol. 10, Issue 4, pp. 178-188.
Ahmed et al., “Regulation of Placental Vascular Endothelial Growth Factor (VEGF) and Placenta Growth Factor (PIGF) and Soluble Flt-1 by Oxygen—A Review,”Placenta21:S16-S24 (2000).
Baek et al., “Hypoxia-Induced VEGF Enhances Tumor Survivability Via Suppression of Serum Deprivation-Induced Apoptosis,”Oncogene19:4621-4631 (2000).
Barleon et al., “Soluble VEGFR-1 Secreted by Endothelial Cells and Monocytes is Present in Human Serum and Plasma from Healthy Donors,”Angiogenesis4:143-154 (2001).
Baumgartner et al., “Constitutive Expression of phVEGF165After Intramuscular Gene Transfer Promotes Collateral Vessel Development in Patients with Critical Limb Ischemia,”Circulation97:1114-1123 (1998).
Belgore et al., “Measurement of Free and Complexed Soluble Vascular Endothelial Growth Factor Receptor, Flt-1, in Fluid Samples: Development and Application of Two New Immunoassays,”Clin. Sci. 100:567-575 (2001).
Belgore et al., “Plasma Levels of Vascular Endothelial Growth Factor and Its Soluble Receptor (SFlt-1) in Essential Hypertension,”Am. J. Cardiol. 87:805-807 (2001).
Belgore et al., “sFlt-1, a Potential Antagonist for Exogenous VEGF,”Circulation102:E108-E109 (2000).
Belgore et al., “Successful Therapy Reduces Levels of Vascular Endothelial Growth Factor (VEGF) in Patients with Hypertension and Patients with Hypercholesterolemia,”Atherosclerosis151:599 (2000).
Belgore et al., “Vascular Endothelial Growth Factor and its Receptor, Flt-1, in Smokers and Non-Smokers,”Br. J. Biomed. Sci. 57:207-213 (2000).
Blann et al., “Plasma Vascular Endothelial Growth Factor and Its Receptor Flt-1 in Patients with Hyperlipidemia and Atherosclerosis and the Effects of Fluvastatin or Fenofibrate,”Am. J. Cardiol. 87:1160-1163 (2001).
Bouletreau et al., “Hypoxia and VEGF Up-Regulate BMP-2 mRNA and Protein Expression in Microvascular Endothelial Cells: Implications for Fracture Healing,”Plast. Reconstr. Surg. 109:2384-2397 (2002).
Celletti et al., “Effect of Human Recombinant Vascular Endothelial Growth Factor165 on Progression of Atherosclerotic Plaque,”J. Am. Coll. Cardiol. 37:2126-2130 (2001).
Charnock-Jones et al., Determination of the Circulating Levels of the Soluble Form of the VEGF-R1 (sFlt-1) in Women at High Risk of Developing Pre-Eclampsia,J. Soc. Gynecol. Investig. 10:166A Abstract No. 230 (2003).
Charnock-Jones et al., “Identification and Localization of Alternately Spliced mRNAs for Vascular Endothelial Growth Factor in Human Uterus and Estrogen Regulation in Endometrial Carcinoma Cell Lines,”Biol. Reprod. 48:1120-1128 (1993).
Clark et al., “A Vascular Endothelial Growth Factor Antagonist is Produced by the Human Placenta and Released into the Maternal Circulation,”Biol. Reprod. 59:1540-1548 (1998).
Cockell et al., “Human Placental Syncytiotrophoblast Microvillous Membranes Impair Maternal Vascular Endothelial Function,”Br. J. Obstet. Gynaecol. 104:235-240 (1997).
Cohen et al., “Amelioration of Diabetic Nephropathy by Treatment with Monoclonal Antibodies Against Glycated Albumin,”Kidney Int. 45:1673-1679 (1994).
Deodato et al., “Recombinant AAV Vector Encoding Human VEGF165 Enhances Wound Healing,”Gene Ther. 9:777-785 (2002).
Eddahibi et al., “Imbalance Between Platelet Vascular Endothelial Growth Factor and Platelet-Derived Growth Factor in Pulmonary Hypertension,”Am. J. Respir. Crit. Care Med. 162:1493-1499 (2000).
Eremina et al., “Glomerular-Specific Alterations of VEGF-A Expression Lead to Distinct Congenital and Acquired Renal Diseases,”J. Clin. Invest. 111:707-716 (2003).
Ferguson, “Meeting Highlights: Highlights of the 48thScientific Sessions of the American College of Cardiology,”Circulation100:570-575 (1999).
Ferrara et al., “The Role of Vascular Endothelial Growth Factor in Angiogenesis,”Acta Haematol. 106:148-156 (2001).
Freedman et al., “Therapeutic Angiogenesis for Coronary Artery Disease,”Ann. Intern. Med. 136:54-71 (2002).
Gille et al., “Analysis of Biological Effects and Signaling Properties of Flt-1 (VEGFR-1) and KDR (VEGFR-2),”J. Biol. Chem. 276:3222-3230 (2001).
Graubert et al., “Vascular Repair After Menstruation Involves Regulation of Vascular Endothelial Growth Factor-Receptor Phosphorylation by sFLT-1,”Am. J. Pathol. 158:1399-1410 (2001).
Hayashi et al., “Changes in Urinary Excretion of Six Biochemical Parameters in Normotensive Pregnancy and Preeclampsia,”Am. J. Kidney Dis. 39:392-400 (2002).
He et al., “Alternative Splicing of Vascular Endothelial Growth Factor (VEGF)-R1 (FLT-1) Pre-mRNA is Important for the Regulation of VEGF Activity,”Mol. Endocrinol. 13:537-45 (1999).
He et al., “Vascular Endothelial Growth Factor Signals Endothelial Cell Production of Nitric Oxide and Prostacyclin through Flk-1/KDR Activation of c-Src,”J. Biol. Chem. 274:25130-25135 (1999).
Heeschen et al., “Nicotine Stimulates Angiogenesis and Promotes Tumor Growth and Atherosclerosis,”Nat. Med. 7:833-839 (2001).
Henry, et al., “Intracoronary Administration of Recombinant Human Vascular Endothelial Growth Factor to Patients with Coronary Artery Disease,”Am. Heart J. 142:872-880 (2001).
Holzgreve et al., “Disturbed Feto-Maternal Cell Traffic in Preeclampsia,”Obstet. Gynecol. 91:669-672 (1998).
Hornig et al., “Release and Complex Formation of Soluble VEGFR-1 from Endothelial Cells and Biological Fluids,”Lab. Invest. 80:443-454 (2000).
Isner et al., “VEGF Gene Transfer for Diabetic Neuropathy,”Hum. Gene Ther. 12:1593-1594 (2001).
Isner, “Myocardial Gene Therapy,”Nature415:234-239 (2002

Affiliated with

Also associated with

Rating

Methods of diagnosing pre-eclampsia or eclampsia does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Methods of diagnosing pre-eclampsia or eclampsia, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of diagnosing pre-eclampsia or eclampsia will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4000657